Gregor Wick, CEO of Angios will have the same role at Aerocyte. The new venture will focus on developing novel treatments for chronic obstructive pulmonary disease (COPD).
COPD is a chronic lung disease that is characterized by chronic lung inflammation causing progressive destruction of gas exchanging lung tissue. Annually, COPD causes over 3 million deaths worldwide. Current therapies aim at halting progression and ameliorating symptoms, but there are no approved treatments targeting the reversal of lung damage. Aerocyte aims to functionally replace lost lung tissue by developing a cell therapy in which lung epithelial cells and blood vessels will be co-transplanted into the lung. Aerocyte combines the organ engineering expertise of Harald Ott, who heads the Center for Organ Engineering at theHarvard Stem Cell Institute and Angios, who develop a new protocol to raise blood vessels in vitro.
Based in Innsbruck, Austria, Aerocyte combines Angios’ vascular engineering technology and Harald Ott’s expertise in generating lung epithelial cells.
Based in Innsbruck, Austria, Angios is a biotechnology company focused on developing therapeutics for vascular diseases with a vision of improving standard of care for diabetic retinopathy and regenerating lost vasculature in several diseases. For more information visit www.angios-bio.com
About Harald C. Ott, M.D.
Harald Ott heads a laboratory at the Harvard Stem Cell Institute, where he focuses on organ engineering as a theoretical alternative to transplantation. Harald is also founder of IVIVA Medical, who develop autologous tissue constructs as a solution to end-stage renal disease (ESRD). To learn more, visit: https://hsci.harvard.edu/people/harald-c-ott-md and https://ivivamedical.com